Acute leukemias (both myeloid and lymphoblastic) are a group of diseases for which each
year more successful therapies are implemented. However, in a subset of cases the overall …

Acute myeloid leukaemia (AML) is a heterogenous disease. Prognosis of AML is influenced
both by patient‐specific as well as disease‐specific factors. Age is the most prominent …

Purpose To determine the frequency of TET2 mutations, their associations with clinical and
molecular characteristics and outcome, and the associated gene-and microRNA-expression …

We previously reported a benefit for all-trans retinoic acid (ATRA) in both induction and
maintenance therapy in patients with acute promyelocytic leukemia (APL). To determine the …

Recent evidence suggests that natural killer (NK) cells are typically defective in infiltrating
solid tumors, with the exception of gastrointestinal stromal tumors (GIST). Interestingly …

We investigated the prognostic relevance of immunophenotype and other clinical
pathological features in 379 adult patients with de novo (acute myeloid leukemia) AML …

The expression of CD56 antigen in acute promyelocytic leukemia (APL) blasts has been
associated with short remission duration and extramedullary relapse. We investigated the …

This article reviews the use of aberrant antigen expression detected by flow cytometry in the
diagnosis and clinical handling of acute myeloid leukaemia (AML) and the myelodysplastic …

Neural cell adhesion molecule 1 (NCAM1; CD56) is expressed in up to 20% of acute
myeloid leukemia (AML) patients. NCAM1 is widely used as a marker of minimal residual …

All trans retinoic acid (ATRA) has revolutionized the therapy of acute promyelocytic leukemia
(APL). Treatment of this leukemia with ATRA in combination with chemotherapy has resulted …